<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03740529</url>
  </required_header>
  <id_info>
    <org_study_id>LOXO-BTK-18001</org_study_id>
    <nct_id>NCT03740529</nct_id>
  </id_info>
  <brief_title>A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL</brief_title>
  <official_title>A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loxo Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loxo Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL
      and NHL who have failed or are intolerant to standard of care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study includes 3 parts: phase 1 (LOXO-305 monotherapy dose escalation and dose
      expansion), phase 1b (LOXO-305 combination therapy dose expansion), and phase 2 (LOXO-305
      monotherapy dose expansion). In phase 1, patients will be enrolled using an accelerated
      titration design. The starting dose of LOXO-305 in oral tablet form is 25 mg/day (e.g., 25 mg
      once daily [QD]). Once the MTD and/or RP2D is identified in phase 1 dose escalation,
      enrollment will continue to phase 1 dose expansion and can commence to phase 1b (Arms A and
      C). Subsequent enrollment to phase 1b (Arm B) and phase 2 will follow when appropriate. For
      phase 2, patients will be enrolled to one of six phase 2 dose expansion cohorts depending on
      tumor histology, tumor genotype, and prior treatment history. Cycle length will be 28 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2018</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase I</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose for further study</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase I</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the preliminary anti-tumor activity of LOXO-305 based on ORR as assessed by an Independent Review Committee (IRC).</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Phase II</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety of LOXO-305 in combination with venetoclax (Arm A) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>For Phase 1b</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety of LOXO-305 in combination with venetoclax and rituximab (Arm B) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>For Phase 1b</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety of LOXO-305 in combination with R-CHOP (Arm C) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>For Phase 1b</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the safety profile and tolerability of LOXO-305 including acute and chronic toxicities by collecting and evaluating Adverse events and treatment emergent adverse events.</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics (PK) properties of LOXO-305 by collecting and evaluating serum at protocol specified time points.</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the preliminary anti-tumor activity of LOXO-305 based on overall response rate (ORR) as assessed by investigator.</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR as assessed by the Investigator.</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR) as assessed by the Investigator and IRC.</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) as assessed by the Investigator and IRC.</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) as assessed by the Investigator and IRC.</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS).</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the safety profile and tolerability of LOXO-305 including acute and chronic toxicities by collecting and evaluating Adverse events and treatment emergent adverse events.</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics (PK) properties of LOXO-305 by collecting and evaluating serum at protocol specified time points.</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic properties and interactions between LOXO-305 and combination drugs by evaluating serum at specified time points</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>For Phase 1b</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the preliminary anti-tumor activity of LOXO-305 in combination based on overall response rate (ORR) as assessed by investigator.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>For Phase 1b</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">403</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>B-cell Lymphoma</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Phase I Dose Escalation (LOXO-305) Monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation and determination of MTD; multiple dose levels of LOXO-305 to be evaluated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Dose Expansion (LOXO-305 Monotherapy) Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WM/MCL/MZL Failed BTKi C481 mutant will receive the recommended Phase 2 dose of LOXO-305.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Dose Expansion (LOXO-305 Monotherapy) Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLL/SLL Failed BTKi C481 mutant will receive the recommended Phase 2 dose of LOXO-305.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Dose Expansion (LOXO-305 Monotherapy) Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WM/MCL/MZL Failed BTKi no C481 mutation will receive the recommended Phase 2 dose of LOXO-305.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Dose Expansion (LOXO-305 Monotherapy) Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLL/SLL Failed BTKi no C481 mutant will receive the recommended Phase 2 dose of LOXO-305.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Dose Expansion (LOXO-305 Monotherapy) Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLL/SLL/WM/MCL/MZL/other NHL intolerant to prior BTKi will receive the recommended Phase 2 dose of LOXO-305.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Dose Expansion (LOXO-305 Monotherapy) Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unknown BTK C481 substitution mutation and other patients not meeting the definitions of Cohorts 1 through 5 will receive the recommended Phase 2 dose of LOXO-305.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Dose Expansion (LOXO-305 Monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients to receive the recommended Phase 2 dose of LOXO-305.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relapsed/Refractory CLL will receive the recommended Phase 2 dose of LOXO-305 in combination with Venetoclax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relapsed/Refractory CLL will receive the recommended Phase 2 dose of LOXO-305 in combination with Venetoclax and Rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD20(+) non-GCB DLBCL/FL/MCL with less than or equal to 1 prior regimen of treatment and greater than or equal to 1 site of measurable disease will receive the recommended Phase 2 dose of LOXO-305 in combination with Rituximab-CHOP (R-CHOP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LOXO-305</intervention_name>
    <description>Oral LOXO-305</description>
    <arm_group_label>Phase 1 Dose Expansion (LOXO-305 Monotherapy)</arm_group_label>
    <arm_group_label>Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm A</arm_group_label>
    <arm_group_label>Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm B</arm_group_label>
    <arm_group_label>Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm C</arm_group_label>
    <arm_group_label>Phase 2 Dose Expansion (LOXO-305 Monotherapy) Cohort 1</arm_group_label>
    <arm_group_label>Phase 2 Dose Expansion (LOXO-305 Monotherapy) Cohort 2</arm_group_label>
    <arm_group_label>Phase 2 Dose Expansion (LOXO-305 Monotherapy) Cohort 3</arm_group_label>
    <arm_group_label>Phase 2 Dose Expansion (LOXO-305 Monotherapy) Cohort 4</arm_group_label>
    <arm_group_label>Phase 2 Dose Expansion (LOXO-305 Monotherapy) Cohort 5</arm_group_label>
    <arm_group_label>Phase 2 Dose Expansion (LOXO-305 Monotherapy) Cohort 6</arm_group_label>
    <arm_group_label>Phase I Dose Escalation (LOXO-305) Monotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Oral</description>
    <arm_group_label>Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm A</arm_group_label>
    <arm_group_label>Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm B</arm_group_label>
    <other_name>Venclexta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>IV</description>
    <arm_group_label>Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm B</arm_group_label>
    <arm_group_label>Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm C</arm_group_label>
    <other_name>Rituxan</other_name>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CHOP</intervention_name>
    <description>IV</description>
    <arm_group_label>Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm C</arm_group_label>
    <other_name>Rituximab (Rituxan)</other_name>
    <other_name>Cyclophosphamide (Cytoxan, Neosar)</other_name>
    <other_name>Doxorubicin (Adriamycin, Rubex)</other_name>
    <other_name>Vincristine (Oncovin, Vincasar PFS)</other_name>
    <other_name>Prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed CLL/SLL, WM, or NHL intolerant to either ≥ 2 prior standard
             of care regimens given in combination or sequentially OR have received 1 prior
             BTK-containing regimen when a BTK inhibitor is approved as first line therapy (Phase 1
             and 2 Patients only).

          -  Adequate hematologic function (Phase 1 and 1b Patients only)

          -  Responsive to transfusion support if given for thrombocytopenia or anemia (Phase 1 and
             1b Patients only)

          -  Histologically confirmed relapsed/recurrent CLL in whom venetoclax is appropriate
             standard salvage treatment (Phase 1b Arm A Patients only)

          -  Histologically confirmed relapsed/refractory CLL in whom venetoclax + rituximab is
             appropriate standard salvage treatment (Phase 1b Arm B Patients only)

          -  Histologically confirmed CD20(+) non-GCB DLBCL, FL, or MCL who have received ≤1 prior
             regimen of treatment, with ≥ 1 site of measurable disease, and for which appropriate
             treatment is the combination of rituximab with standard CHOP (R-CHOP) chemotherapy
             (Phase 1b Arm C Patients only)

          -  Eastern Cooperative Oncology Group (ECOG) 0-2.

          -  Adequate hepatic and renal function.

          -  Ability to receive study drug therapy orally.

          -  Willingness of men and women of reproductive potential to observe conventional and
             effective birth control.

        Exclusion Criteria:

          -  Investigational agent or anticancer therapy within 5 half-lives prior to planned start
             of LOXO-305 except therapeutic monoclonal antibody treatment must be discontinued a
             minimum of 4 weeks prior to the first dose of LOXO-305.. In addition, no concurrent
             investigational therapy is permitted.

          -  Major surgery within 4 weeks prior to planned start of LOXO-305.

          -  Radiotherapy with a limited field of radiation for palliation within 7 days of the
             first dose of study treatment.

          -  Pregnancy or lactation.

          -  Patients requiring therapeutic anticoagulation with warfarin.

          -  Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2
             or greater at the time of starting study treatment except for alopecia.

          -  History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen
             receptor-modified T-cell (CAR-T) therapy within the past 60 days (180 days before the
             PK trigger).

          -  Known central nervous system (CNS) involvement by lymphoma.

          -  Active uncontrolled auto-immune cytopenia where new therapy introduced or concomitant
             therapy escalated within the 4 weeks prior to study enrollment is required to maintain
             adequate blood counts..

          -  Clinically significant, uncontrolled cardiac, cardiovascular disease or history of
             myocardial infarction within 6 months prior to planned start of LOXO-305.

          -  Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.

          -  Tested positive for Human Immunodeficiency Virus (HIV) is excluded.

          -  Clinically significant active malabsorption syndrome.

          -  Current treatment with certain strong cytochrome P450 3A4 (CYP3A4) inhibitors or
             inducers and/or strong P-gp inhibitors

          -  Treatment with proton pump inhibitors (PPIs) within 7 days of starting LOXO-305.

          -  Active second malignancy unless in remission and with life expectancy &gt; 2 years.

          -  Known hypersensitivity to any component or excipient of LOXO-305

          -  Patients with prior significant hypersensitivity to rituximab requiring
             discontinuation, prior allergic or anaphylactic reaction to rituximab (Phase 1b Arm B
             and Arm C Patients only)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Tsai, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Loxo Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>1-855-LOXO-305</phone>
    <email>clinicaltrials@loxooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bita Fakhri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alvaro J Alencar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Manish Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jonathon B Cohen, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jennifer Brown, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Suchitra Sundaram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicole Lamanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anthony Mato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Catherine Coombs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jennifer Woyach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James N Gerson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ian W Flinn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Minal Barve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William G Wierda, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Pagel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nirav Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Constantine Tam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chan Cheah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Steven Le Gouill, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pratia MCM (Małopolskie Centrum Medyczne)</name>
      <address>
        <city>Kraków</city>
        <zip>30510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wojciech Jurczak, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Loxo</keyword>
  <keyword>LOXO-305</keyword>
  <keyword>BTK</keyword>
  <keyword>Bruton's tyrosine kinase</keyword>
  <keyword>CLL</keyword>
  <keyword>SLL</keyword>
  <keyword>NHL</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>C481S</keyword>
  <keyword>C481</keyword>
  <keyword>Ibrutinib</keyword>
  <keyword>Acalabrutinib</keyword>
  <keyword>Zanubrutinib</keyword>
  <keyword>BGB-3111</keyword>
  <keyword>GS-4059</keyword>
  <keyword>ONO-4059</keyword>
  <keyword>Tirabrutinib</keyword>
  <keyword>Small Lymphocytic Lymphoma</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>BTK Intolerant</keyword>
  <keyword>C481S Mutation</keyword>
  <keyword>Marginal zone lymphoma</keyword>
  <keyword>DLBCL (Diffuse Large B-cell lymphoma)</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>PI3KD</keyword>
  <keyword>Idelalisib</keyword>
  <keyword>Umbralisib</keyword>
  <keyword>BCL2</keyword>
  <keyword>Venetoclax</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Rituximab-CHOP (R-CHOP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

